18F-FDG PET/LOW DOSE CT AS UNIQUE IMAGING TECHNIQUE TO ASSESS BONE INVOLVEMENT IN MULTIPLE MYELOMA PATIENTS

EHA Library, Carla Minoia, 297998

FEASIBILITY OF TANDEM AUTOLOGOUS STEM CELL TRANSPLANT FOR HIGH RISK MULTIPLE MYELOMA AT A SINGLE UK CENTRE

EHA Library, Huw Richards, 297999

COMPARISON OF EFFICACY, SAFETY, PATIENTS’ QUALITY OF LIFE AND DOCTORS' OCCUPATIONAL STRESS BETWEEN LENALIDOMIDE BASED AND BORTEZOMIB BASED INDUCTION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Juan Li, 298000

REAL WORLD EXPERIENCE WITH LENALIDOMIDE DEXAMETHASONE DOUBLET THERAPY IN 278 HUNGARIAN PATIENTS

EHA Library, Gergely Varga, 298001

EFFICACY AND SAFETY OF DARATUMUMAB IN THE TREATMENT OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA, LOCAL EXPERIENCE FROM SAUDI ARABIA

EHA Library, Muteb Althomali, 298002

COMORBIDITY IN MULTIPLE MYELOMA IN REAL CLINICAL PRACTICE

EHA Library, Natalia Skvortsova, 298003

LENALIDOMIDE MAINTENANCE THERAPY IN MULTIPLE MYELOMA: A REAL-LIFE SINGLE CENTRE EXPERIENCE

EHA Library, Carolina Afonso, 298004

PROFILE OF RENAL INVOLVEMENT IN MULTIPLE MYELOMA AND ITS REVERSIBILITY WITH BORTEZOMIB BASED TRIPLE DRUG CHEMOTHERAPY

EHA Library, Tribikram Panda, 298005

VCD COMBINATION PRIOR TO VRD TREATMENT IN TRANSPLANT INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA.

EHA Library, Helene Gardeney, 298006

VCD VERSUS VRD-BASED REGIMENS AS FIRST LINE THERAPIES IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA (MM): RETROSPECTIVE MULTICENTER ANALYSIS

EHA Library, Olga Novosad, 298007

PLASMA CELL LEUKEMIA. A 12-YEAR SINGLE CENTER EXPERIENCE.

EHA Library, Javier Alberto Rojas Martínez, 298008

USE OF DIRECT ORAL ANTICOAGULANTS AS PRIMARY OR SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH MULTIPLE MYELOMA ON IMMUNOMODULATORY DRUGS

EHA Library, Carlos Aguilar Franco, 298009

SALVAGE TREATMENT WITH SECOND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN THE MULTIPLE MYELOMA RELAPSE/REFRACTORY SETTING

EHA Library, Luis Miguel Silva, 298010

DARATUMUMAB AS SINGLE AGENT IN RELAPSED REFRACTORY MYELOMA PATIENTS: A RETROSPECTIVE REAL-LIFE SURVEY

EHA Library, Uros Markovic, 298011

EFFICACY AND TOXICITY OF COMBINATION POMALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE IN THE TREATMENT OF REFRACTORY RECURRENT MULTIPLE MYELOMA (RRMM) AT MOSCOW CITY CENTER FOR HEMATOLOGY

EHA Library, Yulia Kochkareva, 298012

SUBCUTANEOUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE PRIOR TO AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA. A RETROSPECTIVE ANALYSIS OF THE CATALAN INSTITUTE OF ONCOLOGY (ICO).

EHA Library, David Jimenez Ruiz De La Torre, 298013

ALLOGENEIC STEM CELL TRANSPLANTATION AFTER COMBINATION OF POMALIDOMIDE AND TEMOZOLOMIDE IN MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT: A CASE STUDY

EHA Library, Omer Ekinci, 298014

NEWLY DIAGNOSED MULTIPLE MYELOMA < 70 – ROUTINE CLINICAL DATA

EHA Library, Joana Santos, 298015

MULTIPLE MYELOMA: RETROSPECTIVE ANALYSIS OF PATIENT RECORDS FROM A HOSPITAL-BASED CANCER REGISTRY AT A SINGLE BRAZILIAN CANCER CENTER

EHA Library, FERNANDA MOURA, 298016

THE ROLE OF DARATUMUMAB, LENALIDOMIDE AND DEXAMETASONE (DRD) IN ACHIEVING DIALYSIS-INDEPENDENCE IN RELAPSING/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)

EHA Library, Joana Oliveira, 298017

BONE DISEASE AS THE FIRST MANIFESTATION OF SYSTEMIC AL-AMYLOIDOSIS

EHA Library, Irina Rekhtina, 298018

EPIDEMIOLOGICAL DATA ON MULTIPLE MYELOMA IN ALBANIA

EHA Library, Tatjana Caja, 298019

EPIDEMIOLOGICAL, CLINICAL, THERAPEUTIC AND PROGRESSIF PROFILE OF 129 CASES OF MULTIPLE MYELOMA

EHA Library, hajar khibri, 298020

PROGRESSION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) TO HAEMATOLOGICAL MALIGNANCY: A SYSTEMATIC REVIEW

EHA Library, Stephen James Quinn, 298021

REAL WORLD USE OF TRANSITIONING FROM BORTEZOMIB TO IXAZOMIB WITH NEWLY DIANOSED MULTIPLE MYELOMA

EHA Library, Yuping Zhong, 298022

SURVIVAL IMPROVEMENT OF OLDER PATIENTS WITH MULTIPLE MIELOMA IN THE ERA OF NOVEL AGENTS. ONE CENTER EXPERIENCE.

EHA Library, Maria Stefania Infante, 298023

POMALIDOMIDE IN MULTIPLE MYELOMA, DESCRIPTIVE ANALYSIS OF OUR EXPERIENCE

EHA Library, Olga Perez-Lopez, 298024

REAL WORLD USE OF POMALIDOMIDE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: CROATIAN EXPERIENCE

EHA Library, Josip Batinić, 298025

POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMA

EHA Library, Claudio Cerchione, 298026

DETERMINANTS OF PERSISTENT IN VIVO PLATELET ACTIVATION IN ASPIRIN-TREATED POLYCYTHEMIA VERA PATIENTS

EHA Library, Paola Ranalli, 298027

CLINICAL ASPECT OF PRECISE DIAGNOSIS IN PATIENTS WITH ERYTHROCYTOSIS

EHA Library, Aleša Kristan, 298028

MOLECULAR PROFILE OF CALR POSITIVE MYELOFIBROSIS: A SINGLE CENTER EXPERIENCE

EHA Library, Daniela Pereira Coelho, 298029

ASSOCIATION OF 46/1 HAPLOTYPE AND V617F MUTATION IN THE JANUS KINASE 2 GENE (JAK2): GENDER AND AGE MATTER

EHA Library, Igor Olkhovskiy, 298030

CONTEMPORARY HFE AND ASXL1 MUTATION IN A PATIENT WITH IDIOPATHIC ERYTHROCYTOSIS

EHA Library, Giacomo Biagetti, 298031

TWO CASES OF MYELOPROLIFERATIVE NEOPLASM WITH DUAL POSITIVITY ( BCR-ABL AND JAK-2)

EHA Library, Amarjot Kaur, 298032

SURVIVAL AND CLONAL EVOLUTION IN ESSENTIAL THROMBOCYTHEMIA AND ITS RELATIONSHIP WITH THE MOLECULAR PROFILE AND CYTOREDUCTIVE TREATMENT

EHA Library, Lucia Mezquita, 298033

CHALLENGING DIAGNOSTIC ASSESSMENT OF GERMLINE RUNX1 VARIANTS IN MYELOID MALIGNANCIES: A CASE REPORT OF A PATIENT PRESENTING WITH A NOVEL GERMLINE RUNX1 VARIANT.

EHA Library, Barbara Cauwelier, 298034

CHRONIC MYELOID LEUKEMIA – SO MANY MUTATIONS, BUT BACK TO THE START

EHA Library, Carolina Pavao, 298035

ASXL1 GENE MUTATIONS IN RUSSIAN PATIENTS WITH PH NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Svetlana Treglazova, 298036

INDIRECT TREATMENT COMPARISON OF THE EFFECT OF FEDRATINIB VERSUS BEST AVAILABLE THERAPY ON SPLEEN VOLUME AND SYMPTOMS FOR PATIENTS WITH MYELOFIBROSIS AND PRIOR RUXOLITINIB TREATMENT

EHA Library, Derek Tang, 298037

ANALYSIS OF A CASE OF ESSENTIAL THROMBOCYTHEMIA WITH CALR MUTATION WHO ACQUIRED ADDITIONAL JAK2 MUTATION IN THE SAME CLONE

EHA Library, Keiki Nagaharu, 298038

TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA: NOT PER SE LOW RISK. A CASE SERIES OF 22 PATIENTS

EHA Library, Parvis Sadjadian, 298039

SCORE CHART FOR CARDIOVASCULAR RISK AND JAK2 V617F MUTATIONS IDENTIFIES CHRONIC MYELOPROLIFERATIVE NEOPLASMS PATIENTS AT HIGH RISK FOR THROMBOTIC EVENT

EHA Library, Novella Pugliese, 298040

FIRST CLINICAL DATA OF THE PAN LYSYL OXIDASE INHIBITOR, PXS-5505, TO TREAT MYELOFIBROSIS

EHA Library, Wolfgang Jarolimek, 298041

CHRONIC KIDNEY DISEASE COULD BE A RISK FACTOR FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA

EHA Library, Ivan Krecak, 298042

PLATELET AND COAGULATIVE ABNORMALITIES IN POLYCYTHEMIA VERA PATIENTS: THROMBOTIC RISK

EHA Library, EMMA CACCIOLA, 298043

MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE BY WHO 2008 CLASSIFICATION, IS REALLOCATED TO PREFIBROTIC PMF AND OVERT PMF ACCORDING TO WHO 2016 CLASSIFICATION

EHA Library, Jiwon Yun, 298044

PHASE 2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE 3 BETA (GSK-3Β) INHIBITOR, AS A SINGLE AGENT OR COMBINED WITH RUXOLITINIB, IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Francis Giles, 298045

A CLINICAL AUDIT ON COMPLIANCE WITH BRITISH SOCIETY OF HAEMATOLOGY GUIDELINES FOR DIAGNOSIS AND MANAGEMENT OF PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Farheen Karim, 298047

CHARACTERISTICS AND FEATURES OF NON-CAUCASIAN MYELOPROLIFERATIVE NEOPLASM PATIENTS IN THE MYMPN REGISTRY

EHA Library, Robyn Scherber, 298048

DOES THE PLATELETS JAK2 V617F ALLELE BURDEN IS AN INDEPENDENT DIAGNOSTIC VALUE IN MPN PATIENTS?

EHA Library, Igor Olkhovskiy, 298049

TRENDS IN OVERALL MORTALITY AMONG US VETERANS WITH INTERMEDIATE / HIGH-RISK PRIMARY MYELOFIBROSIS

EHA Library, Shreekant Parasuraman, 298050

INCREASED RISK OF BCR-ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASM IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED STUDY

EHA Library, Jian Huang, 298051

CDC25C EXPRESSION IN PATIENTS WITH MYELOFIBROSIS IS ASSOCIATED WITH STRONGER MYELOPROLIFERATION AND SHORTER OVERALL SURVIVAL

EHA Library, Davor Galusic, 298052

GENETIC TESTING OF PATIENTS WITH ERYTHROCYTOSIS

EHA Library, Tatiana Subbotina, 298053

PATTERNS OF HYDROXYUREA PRESCRIPTION AND USE IN ROUTINE CLINICAL MANAGEMENT OF POLYCYTHAEMIA VERA: A MULTICENTRE CHART REVIEW STUDY

EHA Library, Tulin Tuglular, 298054

GRAY-ZONE MYELOID NEOPLASMS WITH FEATURES INTERMEDIATE BETWEEN PRIMARY MYELOFIBROSIS AND CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Yanitsa Davidkova, 298055

HIGHER SERUM URIC ACID IS ASSOCIATED WITH HIGHER RISKS OF THROMBOTIC EVENTS AND DEATH IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Marko Lucijanic, 298056

PILOT TRIAL OF LOW-DOSE CYTARABINE FOR HIGH-RISK PATIENTS WITH POST-POLYCYTHEMIA VERA MYELOFIBROSIS IN UKRAINE

EHA Library, Rostyslav Lozynskyy, 298057

PREDICTORS OF REACTIVE OXYGEN SPECIES LEVELS AND TOTAL ANTIOXIDANT CAPACITY IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Mihnea-Alexandru Găman, 298058

COMPARISON OF THE STARTING DOSE OF ANAGRELIDE AS A FIRST-LINE THERAPY IN PATIENTS WITH CYTOREDUCTIVE THERAPY-NAÏVE ESSENTIAL THROMBOCYTHEMIA: DIFFERENCE BETWEEN STARTING AT 0.5 AND 1.0 MG/DAY

EHA Library, Yoshinori Hashimoto, 298059

TREATMENT OF SKIN ITCH IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS: ONE CENTER EXPERIENCE

EHA Library, Yury Shatokhin, 298060

THE VALUE OF MPN10 TO ASSESS SYMPTOM BURDEN IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Tatyana Ionova, 298061

PROFILE OF RUXOLITINIB AND ITS POTENTIAL INFECTIVE COMPLICATIONS IN THE MYELOFIBROSIS TREATMENT.

EHA Library, Harberth Fernandez-Leyva, 298062

INFLUENCE OF CHEK2 MUTATIONS IN MYELOPROLIFERATIVE NEOPLASM: ONE CENTRE EXPERIENCE

EHA Library, Ruta Dambrauskiene, 298063

PEGYLATED INTERFERON ALFA-2A IS EFFECTIVE AND DECREASES LDH LEVELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA

EHA Library, Omer Ekinci, 298064

CLINICAL EXPERIENCE OF SINGLE CENTER IN RUXOLITINIB-TREATMENT OF NON-SELECTIVE GROUP OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Yulia Chernykh, 298065

MINOR VARIANT FINDER SOFTWARE HELPS TO DETECT OF SOMATIC MUTATIONS IN THE ASXL1 AND JAK2 GENES IN CMN

EHA Library, Tatiana Subbotina, 298066

BENEFITS AND SIDE EFFECTS OF RUXOLITINIB TREATMENT IN ROMANIAN PATIENTS DIAGNOSED WITH MYELOFIBROSIS IN THE FUNDENI CLINICAL INSTITUTE

EHA Library, Iulia Ursuleac, 298067

LONGTERM EFFICACY OF ANAGRELIDE, BASED ON ESSENTIAL THROMBOCYTHEMIA PATIENT REGISTRY

EHA Library, Osman Ilhan, 298068

HOW DOES 2016 WHO CRITERIA FOR POLYCYTHEMIA VERA CONTRIBUTE TO OUR DAILY PRACTICE?: A SINGLE-CENTER STUDY FROM TURKEY

EHA Library, Rafet Eren, 298069

PRIMARY MYELOFIBROSIS- CLINICAL, PATHOLOGICAL AND GENETIC PROFILING- A SINGLE CENTER EXPERIENCE

EHA Library, Sarah Elkourashy, 298070

AMBULATORY MANAGEMENT WITH ORAL ETOPOSIDE (VP-16) IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Raquel Iglesias Varela, 298071

PLATELET INDICES PROLIFERATIVE PREDICTIVE ROLE IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Liri Seraj, 298072

JAK2V617F MUTATION AS A RISK FACTOR FOR HAEMORRHAGIC COMPLICATIONS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Evica Simonovic, 298073

BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: TWO DECADES EXPERIENCE OF A CENTER IN CORDOBA, ARGENTINA.

EHA Library, Daiana Rodriguez, 298074

RUXOLITINIB IN REAL CLINICAL PRACTICE IN MOSCOW CITY CENTER FOR HEMATOLOGY

EHA Library, Maria Pankrashkina, 298075

OCCUPATIONAL EXPOSURE IN HEMATOLOGIC MALIGNANCIES: A SERIES OF CASES

EHA Library, Khouloud TOUIHRI, 298076

INTERFERON ALPHA IN THE TREATMENT OF BCR-ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Catia Reis, 298077

OUTCOMES IN PV AND ET ARE AFFECTED BY AGE, THROMBOSIS, JAK2 STATUS AND SECOND CANCERS: LONG-TERM FOLLOW-UP FROM A DISTRICT GENERAL HOSPITAL.

EHA Library, Luke Attwell, 298078

RELATIONSHIP OF JAK 2 V617F MUTATION ALLELE BURDEN WITH DIFFERENT TREATMENT PROTOCOLS AND SMOKING IN POLISTEMIA VERA CASES

EHA Library, Itir Sirinoglu Demiriz, 298079

HEMATOLOGICAL IMPROVEMENT IN A PATIENT WITH ADVANCED PRIMARY MYELOFIBROSIS TREATED WITH RUXOLITINIB AND DEFERASIROX: A CASE REPORT

EHA Library, Erminia Rinaldi, 298080

JAK2V617F MUTATION AS A RISK FACTOR FOR COMPLICATIONS IN PATIENTS WITH PRIMARY MYELOFIBROSIS

EHA Library, Evica Simonovic, 298081

OUTCOME PREDICTION BY INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA RECEIVING THE BEGEV REGIMEN

EHA Library, Carmelo Carlo-Stella, 298082

EARLY HIGH-DOSE SALVAGE AFTER “ABVD X 2 FAILURE” IN HODGKIN’S LYMPHOMA: A PET AND CLINICAL-DRIVEN STRATEGY IN REAL LIFE PRACTICE.

EHA Library, Jacopo Olivieri, 298083

COLLECTION OF PERIPHERAL STEM CELLS IN ADULT HODGKIN'S LYMPHOMA:A STUDY OF RISK FACTORS OF FAILURE

EHA Library, Rym El Fatmi, 298084

IMMUNOTHERAPY WITH NIVOLUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HIV-RELATED LYMPHOMAS

EHA Library, Marina Popova, 298085

THE ROLE OF IMMUNE CHECKPOINT INHIBITORS IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

EHA Library, Anastasiya Beynarovich, 298086

IMPACT OF BODY MASS INDEX (BMI) ON THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA

EHA Library, Talbi Faiza, 298087

CLINICAL AND PROGRESSIVE FEATURES OF PATIENTS WITH AUTOIMMUNE DISEASE ASSOCIATED WITH HODGKIN LYMPHOMA

EHA Library, Talbi Faiza, 298088

EFFECT OF ADULT HODGKIN LYMPHOMA PATIENTS TREATMENT PROCESS ON THEIR RELATIVES

EHA Library, Itir Sirinoglu Demiriz, 298089

INVOLVEMENT OF THE CENTRAL NERVOUS SYSTEM (CNS) IN HODGKIN'S LYMPHOMA (HL)

EHA Library, ABBADI Mohamed Rafik, 298090

LYMPH NODE ACTIVATION ON FDG-PET/CT INDUCED BY INFLUENZA VACCINATION IN HODGKIN LYMPHOMA

EHA Library, Stéphanie Guidez, 298091

SARCOPENIA IN HODGKIN’S LYMPHOMA EVALUATED WITH 18 FDG PET/CT, FOCUS ON AGE, PERFORMANCE AND TREATMENT

EHA Library, Volkan Bas, 298092

PALONOSETRON’S EFFECTIVENESS AS PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN HODGKIN’S DESEASE TREATED IN FIRST-LINE THERAPY WITH ABVD

EHA Library, Raquel Iglesias Varela, 298093

EVALUATION OF THE PREDICTIVE VALUE OF THE PET SCANNER IN HODGKIN LYMPHOMA AFTER 2 TO 3 CYCLES OF CHEMOTHERAPY

EHA Library, Kahina Belateche, 298094

PROGNOSTIC VALUE OF TISSUE-INFILTRATING IMMUNE CELLS IN TUMOR MICROENVIRONMENT OF FOLLICULAR LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Mixue Xie, 298095

PRIMARY CUTANEOUS B-CELL INDOLENT LYMPHOMAS – RETROSPECTIVE MULTICENTRIC ANALYSIS

EHA Library, Magdalena Olszewska-Szopa, 298096

FOCAL, SYMPTOMATIC BONE MARROW LESIONS IN WALDENSTRÖM MACROGLOBULINAEMIA CHARACTERISED BY DENSE INFILTRATION WITH LYMPHOPLASMACYTIC LYMPHOMA: A NEWLY DEFINED INDICATION FOR SYSTEMIC TREATMENT

EHA Library, Suzanne Arulogun, 298097

OBINUTUZUMAB PLUS CHEMOTHERAPY IN FOLLICULAR LYMPHOMA RWD.

EHA Library, Kissy Guevara-Hoyer, 298098